MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$16,563K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Sales and maturities of short-te...
    • Proceeds from issuance of common...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchase of short-term and long-...
    • Accrued expenses
    • Prepaid expenses and other curre...
    • Amortization/accretion of bond d...

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-43,320 -35,544 -34,978 -95,786
Stock-based compensation expense
5,485 3,222 3,716 5,582
Amortization/accretion of bond discounts/premiums
-559 -3,026 NaN NaN
Prepaid expenses and other current assets
2,561 -275 6,490 6,346
Other assets
-37 NaN NaN NaN
Accounts payable
2,807 -8 1,869 280
Accrued expenses
-3,828 4,428 91 2,148
Operating lease liabilities
47 -5 -6 -10
Net cash used in operating activities
-41,892 -30,658 -35,798 -94,132
Purchase of short-term and long-term investments
64,383 151,180 90,369 31,385
Sales and maturities of short-term and long-term investments
67,965 79,981 39,609 82,116
Net cash used in investing activities
3,582 -71,199 -50,760 50,731
Proceeds from issuance of common stock, net of issuance costs
54,724 34,658 167,973 NaN
Proceeds from the exercise of stock options
149 84 49 369
Payment of deferred financing costs
NaN 17 -300 353
Proceeds from issuance of common stock in an initial public offering and atm facility, net of issuance costs
NaN NaN NaN 81,857
Net cash provided by financing activities
54,873 34,725 86,465 81,873
Net increase (decrease) in cash and cash equivalents
16,563 -67,132 -93 38,472
Cash and cash equivalents at beginning of the year
45,540 112,672 74,293 NaN
Cash and cash equivalents at end of the year
62,103 45,540 112,672 NaN
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock, net of...$54,724K Proceeds from theexercise of stock options$149K Sales and maturitiesof short-term and...$67,965K Net cash provided byfinancing activities$54,873K Net cash used ininvesting activities$3,582K Canceled cashflow$64,383K Net increase(decrease) in cash and cash...$16,563K Canceled cashflow$41,892K Stock-based compensationexpense$5,485K Accounts payable$2,807K Operating leaseliabilities$47K Other assets-$37K Purchase of short-termand long-term...$64,383K Net cash used inoperating activities-$41,892K Canceled cashflow$8,376K Net loss-$43,320K Accrued expenses-$3,828K Prepaid expenses andother current assets$2,561K Amortization/accretion of bonddiscounts/premiums-$559K

ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma, Inc. (AVBP)